PRCT Key Statistics, Chart & Performance
The current stock price of PRCT is 32.83 USD. In the past month the price decreased by -8.06%. In the past year, price decreased by -62.2%.
PRCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Related stock screener links
About PRCT
Company Profile
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 756 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Company Info
PROCEPT BIOROBOTICS CORP
150 Baytech Drive
San Jose CALIFORNIA US
CEO: Reza Zadno
Employees: 756
Phone: 16502329832
PROCEPT BIOROBOTICS CORP / PRCT FAQ
What does PRCT do?
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 756 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
What is the current price of PRCT stock?
The current stock price of PRCT is 32.83 USD. The price decreased by -4.79% in the last trading session.
Does PRCT stock pay dividends?
PRCT does not pay a dividend.
What is the ChartMill technical and fundamental rating of PRCT stock?
PRCT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of PROCEPT BIOROBOTICS CORP (PRCT) based on its PE ratio?
PROCEPT BIOROBOTICS CORP (PRCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).
Can you provide the growth outlook for PROCEPT BIOROBOTICS CORP?
The Revenue of PROCEPT BIOROBOTICS CORP (PRCT) is expected to grow by 46.32% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of PRCT stock?
PROCEPT BIOROBOTICS CORP (PRCT) has a market capitalization of 1.83B USD. This makes PRCT a Small Cap stock.
PRCT Technical Analysis
PRCT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PRCT. While PRCT seems to be doing ok healthwise, there are quite some concerns on its profitability.
PRCT Financial Highlights
Over the last trailing twelve months PRCT reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS increased by 21.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.53% | ||
| ROE | -22.24% | ||
| Debt/Equity | 0.14 |
PRCT Forecast & Estimates
20 analysts have analysed PRCT and the average price target is 53.81 USD. This implies a price increase of 63.89% is expected in the next year compared to the current price of 32.83.
For the next year, analysts expect an EPS growth of 12.5% and a revenue growth 46.32% for PRCT